Christensen et al. 2013. Predicting transition temperature of elastin-like polypeptide fusion proteins. Biomacromolecules.
Kowalczyk et al. 2014. Elastin-like polypeptides as a promising family of genetically-engineered protein based polymers. World Journal of Microbiology and Biotechnology.
McDaniel et al. 2013. A unified model for de novo design of elastin-like polypeptides with tunable inverse transition temperatures. Biomacromolecules.
Vasoactive Intestinal Peptide
Alcolado et al. 2014. Cystic fibrosis transmembrane conductance regulator dysfunction in VIP knockout mice. American Journal of Physiology – Cell Physiology.
Alshafie et al. 2014. VIP regulates CFTR membrane expression and function in Calu-3 cells by increasing its interaction with NHERF1 and P-ERM in a VPAC1- and PKCε-dependent manner. American Journal of Physiology – Cell Physiology.
Delgado and Ganea 2013. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids.
Dvorakova and Slavikova 2015. Localization and function of VIP and PACAP in the heart. Edorium Journal of Physiology.
Hamidi et al. 2011. VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension. Respiratory Research.
Henning and Sawmiller 2001. Vasoactive intestinal peptide: cardiovascular effects. Cardiovascular Research.
Igarashi et al. 2011. Vasoactive intestinal peptide (VIP) and VIP receptors—elucidation of structure and function for therapeutic applications. International Journal of Clinical Medicine.
Koga et al. 2014. Role of VPAC2 receptor in monocrotaline-induced pulmonary hypertension in rats. .
Langer 2012. Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies. Frontiers in Endocrinology.
Lee et al. 2013. Vasoactive intestinal peptide regulates sinonasal mucociliary clearance and synergizes with histamine in stimulating sinonasal fluid secretion. The FASEB Journal.
McNally et al. 2015. Contemporary cardiac issues in Duchenne Muscular Dystrophy. Circulation.
Szema et al. 2013. VIP gene deletion in mice causes cardiomyopathy associated with upregulation of heart failure genes. PLOS ONE.
van Westering et al. 2015. Current understanding of molecular pathology and treatment of cardiomyopathy in Duchenne Muscular Dystrophy. Molecules.